RIGEL PHARMACEUTICALS INC — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Rigel Pharmaceuticals executed an exclusive global licensing agreement with Arvinas and Pfizer to commercialize VEPPANU (vepdegestrant), the first FDA-approved PROTAC for ER+/HER2–/ESR1-mutated metastatic breast cancer, paying $70.0M upfront on June 11, 2026, with U.S. commercial availability expected mid-August 2026. Q2 2026 total revenues were $78.7M ($67.0M net product sales, $11.7M contract revenues); net income $17.3M ($0.88 diluted EPS). The company raised full-year 2026 guidance to $285–$295M total revenues (excluding VEPPANU), up from $275–$290M, with contract revenues increased to ~$30M from $20–25M.
Why this rating
VEPPANU acquisition ($70M ≈ 21% of market cap) expands oncology portfolio meaningfully; strong Q2 sales growth (14% YoY) and raised FY26 guidance are encouraging. However, cash fell 38% to $95M; R&D/SG&A costs rising; material risk remains on VEPPANU adoption and competitive dynamics. Moderate trajectory impact for company size.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.